References
-
Jeppesen, D. K., Zhang, Q., Franklin, J. L. & Coffey, R. J. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol. 33, 667–681 (2023).
-
Kishore, R. & Khan, M. More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair. Circ. Res. 118, 330–343 (2016).
-
Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3, 24641 (2014).
-
Dai, J. et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther. 5, 145 (2020).
-
Stahl, P. D. & Raposo, G. Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiology 34, 169–177 (2019).
-
Ferguson, S. W. & Nguyen, J. Exosomes as therapeutics: the implications of molecular composition and exosomal heterogeneity. J. Control. Release 228, 179–190 (2016).
-
Liang, Y., Duan, L., Lu, J. & Xia, J. Engineering exosomes for targeted drug delivery. Theranostics 11, 3183–3195 (2021).
-
Bonacquisti, R. Engineering a genetically-encodable toolkit for tracking extracellular vesicle RNA cargo. PhD thesis, Univ. North Carolina Chapel Hill (2023).
-
Liang, X. et al. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat. Commun. 16, 4028 (2025).
-
Wiklander, O. P. B. et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat. Biomed. Eng. 8, 1453–1468 (2024).
-
Zhang, T., Zhang, L., Ma, X. & Song, W. The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Front. Cell Dev. Biol. 13, 1612589 (2025).
-
Nguyen, J. & Fuhrmann, G. Extracellular vesicles — a versatile biomaterial. Adv. Healthc. Mater. 11, e2200192 (2022).
-
Delen, M. V., Derdelinckx, J., Wouters, K., Nelissen, I. & Cools, N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J. Extracell. Vesicles 13, e12458 (2024).
-
Fraiman, J. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 40, 5798–5805 (2022).
-
Murphy, D. E. et al. Natural or synthetic RNA Delivery: a stoichiometric comparison of extracellular vesicles and synthetic nanoparticles. Nano Lett. 21, 1888–1895 (2021).
-
Kang, M., Jordan, V., Blenkiron, C. & Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J. Extracell. Vesicles 10, e12085 (2021).
-
Anderson, J. D. et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cell 34, 601–613 (2016).
-
Ferguson, S. W. et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci. Rep. 8, 1419 (2018).
-
Chansoria, P. et al. Instantly adhesive and ultra-elastic patches for dynamic organ and wound repair. Nat. Commun. 15, 4720 (2024).
-
Hatzistergos, K. E., Blum, A., Ince, T., Grichnik, J. & Hare, J. M. What is the oncologic risk of stem cell treatment for heart disease? Circ. Res. 108, 1300–1303 (2011).
-
Chiangjong, W., Netsirisawan, P., Hongeng, S. & Chutipongtanate, S. Red blood cell extracellular vesicle-based drug delivery: challenges and opportunities. Front. Med. 8, 761362 (2021).
-
Biagiotti, S. et al. Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules. Sci. Rep. 14, 14610 (2024).
-
Usman, W. M. et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat. Commun. 9, 2359 (2018).
-
Zhang, G. et al. Extracellular vesicles: natural liver-accumulating drug delivery vehicles for the treatment of liver diseases. J. Extracell. Vesicle 10, e12030 (2020).
-
Wu, J., Piao, Y., Liu, Q. & Yang, X. Platelet-rich plasma-derived extracellular vesicles: a superior alternative in regenerative medicine? Cell Prolif. 54, e13123 (2021).
-
Antich-Rosselló, M. et al. Platelet-derived extracellular vesicles for regenerative medicine. Int. J. Mol. Sci. 22, 8580 (2021).
-
Wang, Z., Wang, Q., Qin, F. & Chen, J. Exosomes: a promising avenue for cancer diagnosis beyond treatment. Front. Cell Dev. Biol. 12, 1344705 (2024).
-
Wang, X. et al. Exosomes and cancer — diagnostic and prognostic biomarkers and therapeutic vehicle. Oncogenesis 11, 54 (2022).
-
McNamara, R. P. et al. Exosome-encased nucleic acid scaffold chemotherapeutic agents for superior anti-tumor and anti-angiogenesis activity. ACS Bio Med Chem Au 2, 140–149 (2022).
-
Nguyen, V. D., Kim, H. Y., Choi, Y. H., Park, J.-O. & Choi, E. Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors in vivo. Drug Deliv. 29, 2621–2631 (2022).
-
Feng, L., Guo, L., Tanaka, Y. & Su, L. Tumor-derived small extracellular vesicles involved in breast cancer progression and drug resistance. Int. J. Mol. Sci. 23, 15236 (2022).
-
Guo, X., Sui, R. & Piao, H. Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J. Nanobiotechnol. 20, 383 (2022).
-
Haney, M. J. et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Release 207, 18–30 (2015).
-
Yuan, D. et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1–12 (2017).
-
Aiello, S. et al. Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Sci. Rep. 7, 11518 (2017).
-
Fernández-Messina, L., Gutiérrez-Vázquez, C., Rivas-García, E., Sánchez-Madrid, F. & de la Fuente, H. Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol. Cell 107, 61–77 (2015).
-
Kim, M. S. et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine 14, 195–204 (2018).
-
Williams, A. et al. Targeting of extracellular vesicle-based therapeutics to the brain. Cell 14, 548 (2025).
-
Cheng, L., Wang, Y. & Huang, L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol. Ther. 25, 1665–1675 (2017).
-
Tan, E., Chin, C. S. H., Lim, Z. F. S. & Ng, S. K. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front. Bioeng. Biotechnol. 9, 796991 (2021).
-
Ohno, S.-I. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185–191 (2013).
-
Wang, C. et al. Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy. J. Nanobiotechnol. 20, 247 (2022).
-
Sung, B. H. et al. A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nat. Commun. 11, 2092 (2020).
-
Tieu, A. et al. Biodistribution of mesenchymal stromal cell-derived extracellular vesicles administered during acute lung injury. Stem Cell Res. Ther. 14, 250 (2023).
-
Kronstadt, S. M., Heyningen, L. H. V., Aranda, A. & Jay, S. M. Assessment of anti-inflammatory bioactivity of extracellular vesicles is susceptible to error via media component contamination. Cytotherapy 25, 387–396 (2023).
-
Zhu, X. et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).
-
Saleh, A. F. et al. Extracellular vesicles induce minimal hepatotoxicity and immunogenicity. Nanoscale 11, 6990–7001 (2019).
-
Ferguson, S., Kim, S., Lee, C., Deci, M. & Nguyen, J. The phenotypic effects of exosomes secreted from distinct cellular sources: a comparative study based on miRNA composition. AAPS J. 20, 67 (2018).
-
Hagey, D. W. et al. The cellular response to extracellular vesicles is dependent on their cell source and dose. Sci. Adv. 9, eadh1168 (2023).
-
Escudier, B. et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med. 3, 10 (2005).
-
Maxson, S., Lopez, E. A., Yoo, D., Danilkovitch-Miagkova, A. & LeRoux, M. A. Concise Review: role of mesenchymal stem cells in wound repair. Stem Cell Transl. Med. 1, 142–149 (2012).
-
Wang, J. et al. Boosting the biogenesis and secretion of mesenchymal stem cell-derived exosomes. Cell 9, 660 (2020).
-
Wang, J. et al. MiR-101a loaded extracellular nanovesicles as bioactive carriers for cardiac repair. Nanomedicine 27, 102201 (2020).
-
Jasiewicz, N. E. et al. In situ-crosslinked Zippersomes enhance cardiac repair by increasing accumulation and retention. Bioeng. Transl. Med. 9, e10697 (2024).
-
Zhang, K. & Cheng, K. Stem cell-derived exosome versus stem cell therapy. Nat. Rev. Bioeng. 1, 608–609 (2023).
-
Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960–2974 (2022).
-
Carney, R. P. et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat. Nanotechnol. 20, 14–25 (2024).
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04493242 (2024).
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04491240 (2020).
-
Margiana, R. et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res. Ther. 13, 366 (2022).
-
Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
-
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05523011 (2024).
-
Chandran, N. S. et al. A phase 1, open-label study to determine safety and tolerability of the topical application of mesenchymal stem/stromal cell (MSC) exosome ointment to treat psoriasis in healthy volunteers. Cytotherapy 27, 633–641 (2025).
-
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03608631 (2025).
-
Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).
-
Surana, R. et al. Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. J. Clin. Oncol. 40, TPS633 (2022).
-
Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263 (2018).
-
Kalluri, V. S. et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat. Commun. 16, 8696 (2025).
-
Yang, Y. et al. Acquisition of new tumor cell properties by MSC-derived exosomes. Int. J. Oncol. 47, 244–252 (2015).
-
Roccaro, A. M. et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542–1555 (2013).
-
Zhu, W. et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 315, 28–37 (2012).
-
Wang, J. et al. Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization. Stem Cell Res. Ther. 11, 424 (2020).
-
Zhao, R., Chen, X., Song, H., Bie, Q. & Zhang, B. Dual role of MSC-derived exosomes in tumor development. Stem Cell Int. 2020, 8844730 (2020).
-
Adlerz, K., Patel, D., Rowley, J., Ng, K. & Ahsan, T. Strategies for scalable manufacturing and translation of MSC-derived extracellular vesicles. Stem Cell Res. 48, 101978 (2020).
-
Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, 2403199 (2024).
-
Zeng, F. et al. Graft-derived extracellular vesicles transported across subcapsular sinus macrophages elicit B cell alloimmunity after transplantation. Sci. Transl. Med. 13, eabb0122 (2021).
-
Labusek, N. et al. Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury. Inflamm. Regen. 43, 24 (2023).
-
Shitova, M., Alpeeva, E. & Vorotelyak, E. Review of hTERT-immortalized cells: how to assess immortality and confirm identity. Int. J. Mol. Sci. 25, 13054 (2024).
-
Lin, Y. C. et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 5, 4767 (2014).
-
Lilyestrom, W., Klein, M. G., Zhang, R., Joachimiak, A. & Chen, X. S. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 20, 2373–2382 (2006).
-
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05216562 (2022).
-
Gonzalez-King, H. et al. Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cell 35, 1747–1759 (2017).
-
Arslan, F. et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 10, 301–312 (2013).
-
Jasiewicz, N., Drabenstott, C. & Nguyen, J. Harnessing the full potential of extracellular vesicles as drug carriers. Curr. Opin. Colloid Interface Sci. 51, 101412 (2021).
-
Bader, J., Brigger, F. & Leroux, J.-C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv. Drug Deliv. Rev. 215, 115461 (2024).
-
Zeng, H. et al. Current strategies for exosome cargo loading and targeting delivery. Cells 12, 1416 (2023).
-
Luan, X. et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017).
-
Liu, M. et al. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565–575 (2024).
-
Kim, M. S. et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655–664 (2016).
-
Le Saux, S. et al. Post-production modifications of murine mesenchymal stem cell (mMSC) derived extracellular vesicles (EVs) and impact on their cellular interaction. Biomaterials 231, 119675 (2020).
-
Nizamudeen, Z. A. et al. Low-power sonication can alter extracellular vesicle size and properties. Cells 10, 2413 (2021).
-
Chen, W. Electroconformational denaturation of membrane proteins. Ann. N. Y. Acad. Sci. 1066, 92–105 (2005).
-
Bangham, A. D. & Horne, R. W. Action of saponin on biological cell membranes. Nature 196, 952–953 (1962).
-
Patel, G. K. et al. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 9, 5335 (2019).
-
Linares, R., Tan, S., Gounou, C., Arraud, N. & Brisson, A. R. High-speed centrifugation induces aggregation of extracellular vesicles. J. Extracell. Vesicle 4, 29509 (2015).
-
Li, Z. et al. In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 19, 19–28 (2019).
-
Gee, P. et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat. Commun. 11, 1334 (2020).
-
Chitti, S. V. et al. Vesiclepedia 2024: an extracellular vesicles and extracellular particles repository. Nucleic Acids Res. 52, D1694–D1698 (2023).
-
Keerthikumar, S. et al. ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428, 688–692 (2016).
-
Cvjetkovic, A., Lötvall, J. & Lässer, C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J. Extracell. Vesicles 3, 23111 (2014).
-
Chou, C.-Y. et al. Improving the purity of extracellular vesicles by removal of lipoproteins from size exclusion chromatography- and ultracentrifugation-processed samples. ACS Appl. Mater. Interfaces 16, 44386–44398 (2024).
-
Xabier, O. et al. Differential detergent sensitivity of extracellular vesicle subpopulations. Org. Biomol. Chem. 13, 9775–9782 (2015).
-
Koudelka, Š & Turánek, J. Liposomal paclitaxel formulations. J. Control. Release 163, 322–334 (2012).
-
Alskär, L. C., Porter, C. J. H. & Bergström, C. A. S. Tools for early prediction of drug loading in lipid-based formulations. Mol. Pharm. 13, 251–261 (2016).
-
Tang, T.-T. et al. Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI. Sci. Adv. 6, eaaz0748 (2020).
-
Kirwin, K. et al. 572 Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity. J. Immunother. Cancer 9, A601 (2021).
-
Abusamra, A. J. et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol. Dis. 35, 169–173 (2005).
-
Budayr, O. M., Miller, B. C. & Nguyen, J. Harnessing extracellular vesicle-mediated crosstalk between T cells and cancer cells for therapeutic applications. J. Control. Release 378, 266–280 (2025).
-
Sakla, M., Breitinger, U., Breitinger, H.-G., Mansour, S. & Tammam, S. N. Delivery of trans-membrane proteins by liposomes; the effect of liposome size and formulation technique on the efficiency of protein delivery. Int. J. Pharm. 606, 120879 (2021).
-
Wang, Z. et al. Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2. Nat. Commun. 15, 2236 (2024).
-
Rawlings, A. E. Membrane proteins: always an insoluble problem? Biochem. Soc. Trans. 44, 790–795 (2016).
-
Beit-Yannai, E., Tabak, S. & Stamer, W. D. Physical exosome:exosome interactions. J. Cell Mol. Med. 22, 2001–2006 (2018).
-
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).
-
Kooijmans, S. A. A. et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Release 172, 229–238 (2013).
-
Abreu, R. C. D. et al. Exogenous loading of miRNAs into small extracellular vesicles. J. Extracell. Vesicles 10, e12111 (2021).
-
Maugeri, M. et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat. Commun. 10, 4333 (2019).
-
Lamichhane, T. N., Raiker, R. S. & Jay, S. M. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol. Pharm. 12, 3650–3657 (2015).
-
Bonacquisti, E. E. et al. Fluorogenic RNA-based biomaterials for imaging and tracking the cargo of extracellular vesicles. J. Control. Release 374, 349–368 (2024).
-
Chen, C. et al. Active cargo loading into extracellular vesicles: highlights the heterogeneous encapsulation behaviour. J. Extracell. Vesicles 10, e12163 (2021).
-
Willms, E. et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci. Rep. 6, 22519 (2016).
-
Liao, S. et al. Transfection potency of lipid nanoparticles containing mRNA depends on relative loading levels. ACS Appl. Mater. Interfaces 17, 3097–3105 (2024).
-
Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. Guidance for Industry Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications (FDA, 2003).
-
Qiao, L. et al. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics 10, 3474–3487 (2020).
-
Jurgielewicz, B. J. et al. Kinetics and specificity of HEK293T extracellular vesicle uptake using imaging flow cytometry. Nanoscale Res. Lett. 15, 170 (2020).
-
Sancho-Albero, M. et al. Exosome origin determines cell targeting and the transfer of therapeutic nanoparticles towards target cells. J. Nanobiotechnol. 17, 16 (2019).
-
Rana, S., Yue, S., Stadel, D. & Zöller, M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 44, 1574–1584 (2012).
-
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 7578 (2015).
-
Takov, K., Yellon, D. M. & Davidson, S. M. Confounding factors in vesicle uptake studies using fluorescent lipophilic membrane dyes. J. Extracell. Vesicles 6, 1388731 (2017).
-
Pužar Dominkuš, P. et al. PKH26 labeling of extracellular vesicles: characterization and cellular internalization of contaminating PKH26 nanoparticles. Biochim. Biophys. Acta Biomembr. 1860, 1350–1361 (2018).
-
Dehghani, M., Gulvin, S. M., Flax, J. & Gaborski, T. R. Systematic evaluation of PKH labelling on extracellular vesicle size by nanoparticle tracking analysis. Sci. Rep. 10, 9533 (2020).
-
Simonsen, J. B. Pitfalls associated with lipophilic fluorophore staining of extracellular vesicles for uptake studies. J. Extracell. Vesicles 8, 1582237 (2019).
-
Lau, S. Y., Kang, M., Hisey, C. L. & Chamley, L. W. Studying exogenous extracellular vesicle biodistribution by in vivo fluorescence microscopy. Dis. Model. Mech. 16, dmm050074 (2023).
-
Lai, C. P. et al. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015).
-
Gupta, D. et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J. Extracell. Vesicles 9, 1800222 (2020).
-
Fordjour, F. K., Guo, C., Ai, Y., Daaboul, G. G. & Gould, S. J. A shared, stochastic pathway mediates exosome protein budding along plasma and endosome membranes. J. Biol. Chem. 298, 102394 (2022).
-
Mathieu, M. et al. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat. Commun. 12, 4389 (2021).
-
Lu, C.-H. et al. Preclinical characterization and in vivo imaging of 111In-labeled mesenchymal stem cell-derived extracellular vesicles. Mol. Imaging Biol. 23, 361–371 (2020).
-
Royo, F. et al. Modification of the glycosylation of extracellular vesicles alters their biodistribution in mice. Nanoscale 11, 1531–1537 (2019).
-
Lázaro-Ibáñez, E. et al. Selection of fluorescent, bioluminescent, and radioactive tracers to accurately reflect extracellular vesicle biodistribution in vivo. ACS Nano 15, 3212–3227 (2021).
-
Hwang, D. W. et al. Chemical modulation of bioengineered exosomes for tissue-specific biodistribution. Adv. Therapeutics 2, 1900111 (2019).
-
Gallo, A., Tandon, M., Alevizos, I. & Illei, G. G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 7, e30679 (2012).
-
Mori, M. A., Ludwig, R. G., Garcia-Martin, R., Brandão, B. B. & Kahn, C. R. Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab. 30, 656–673 (2019).
-
Bi, Y. et al. Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells. Cell Metab. 37, 527–541.e6 (2025).
-
Wiklander, O. P. B. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 4, 26316 (2015).
-
Welsh, J. A. et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J. Extracell. Vesicles 13, e12404 (2024).
-
Wortzel, I., Dror, S., Kenific, C. M. & Lyden, D. Exosome-mediated metastasis: communication from a distance. Dev. Cell 49, 347–360 (2019).
-
Raith, M. et al. Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles. J. Control. Release 355, 434–445 (2023).
-
Manca, S. et al. Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns. Sci. Rep. 8, 11321 (2018).
-
Khare, H. A., Bazban-Shotorbani, S., Binderup, T., Kjaer, A. & Kamaly, N. Effect of size and targeting agent on biodistribution of polystyrene nanoparticles in apolipoprotein E knock-out and wild-type mice. Diagnostics 15, 2140 (2025).
-
Zhang, P. et al. In vivo tracking of multiple tumor exosomes labeled by phospholipid-based bioorthogonal conjugation. Anal. Chem. 90, 11273–11279 (2018).
-
Graham Jr, R. C. & Karnovsky, M. J. Glomerular permeability. Ultrastructural cytochemical studies using peroxidases as protein tracers. J. Exp. Med. 124, 1123–1134 (1966).
-
Banks, W. A. et al. Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int. J. Mol. Sci. 21, 4407 (2020).
-
Wu, J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J. Pers. Med. 11, 771 (2021).
-
Peng, Z. et al. Tumor-derived extracellular vesicles enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer. ACS Nano 18, 30943–30956 (2024).
-
Samal, S., Panda, G. P., Shyamal, S., Das, K. & Dash, M. Surface engineered osteoblast-extracellular vesicles serve as an efficient carrier for drug and small RNA to actively target osteosarcoma. ACS Biomater. Sci. Eng. 10, 7466–7481 (2024).
-
Kooijmans, S. A. A. et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J. Control. Release 224, 77–85 (2016).
-
Du, J. et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics 11, 8185–8196 (2021).
-
Alharbi, M. et al. Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering. Int. J. Cancer 155, 1510–1523 (2024).
-
Manjiao, Z. et al. SPION decorated exosome delivery of TNF-α to cancer cell membranes through magnetism. Nanoscale 12, 173–188 (2019).
-
Heidarzadeh, M., Zarebkohan, A., Rahbarghazi, R. & Sokullu, E. Protein corona and exosomes: new challenges and prospects. Cell Commun. Signal. 21, 64 (2023).
-
Willms, E., Cabañas, C., Mäger, I., Wood, M. J. A. & Vader, P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738 (2018).
-
Verderio, C., Gabrielli, M. & Giussani, P. Role of sphingolipids in the biogenesis and biological activity of extracellular vesicles. J. Lipid Res. 59, 1325–1340 (2018).
-
Liu, P., Chen, G. & Zhang, J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules 27, 1372 (2022).
-
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H. & Im, H.-J. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging. Theranostics 12, 7509–7531 (2022).
-
Leung, A. K. K. et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J. Phys. Chem. C Nanomater. Interfaces 116, 18440–18450 (2012).
-
Fuhrmann, G., Serio, A., Mazo, M., Nair, R. & Stevens, M. M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Release 205, 35–44 (2015).
-
Kang, M. et al. Placental extracellular vesicles can be loaded with plasmid DNA. Mol. Pharm. 20, 1898–1913 (2023).
-
Azizah, A. et al. In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression. Biomater. Sci. 10, 2940–2952 (2022).
-
Li, T. et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal. Transduct. Target. Ther. 8, 36 (2023).
-
Wu, F. et al. Lipid nanoparticles for delivery of CRISPR gene editing components. Small Methods 10, e2401632 (2025).
-
Kim, S. M. et al. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J. Control. Release 266, 8–16 (2017).
-
Liu, X. et al. Engineered extracellular vesicle-delivered CRISPR/Cas9 for radiotherapy sensitization of glioblastoma. ACS Nano 17, 16432–16447 (2023).
-
Berggreen, A. H., Petersen, J. L., Lin, L., Benabdellah, K. & Luo, Y. CRISPR delivery with extracellular vesicles: promises and challenges. J. Extracell. Biol. 2, e111 (2023).
-
Chen, R. et al. Friend or foe? evidence indicates endogenous exosomes can deliver functional gRNA and cas9 protein. Small 15, 1902686 (2019).
-
Kazemian, P. et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol. Pharm. 19, 1669–1686 (2022).
-
Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).
-
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
-
Somiya, M., Yoshioka, Y. & Ochiya, T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. J. Extracell. Vesicles 7, 1440132 (2018).
-
Chew, W. L. Immunity to CRISPR Cas9 and Cas12a therapeutics. Wiley Interdiscip. Rev. Syst. Biol. Med. 10, e1408 (2018).
-
Wang, D. et al. Adenovirus-mediated somatic genome editing of pten by CRISPR/Cas9 in mouse liver in spite of cas9-specific immune responses. Hum. Gene Ther. 26, 432–442 (2015).
-
Kim, S. et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 28, 367–373 (2018).
-
Driedonks, T. et al. Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina. J. Extracell. Biol. 1, e59 (2022).
-
Johnsen, K. B. et al. On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems — a commentary. J. Control. Release 269, 10–14 (2018).
-
Chen, K. et al. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein. Nat. Biotechnol. 43, 1445–1457 (2025).
-
Jiang, C. et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res. 27, 440–443 (2017).
-
Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).
-
Wan, T. et al. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci. Adv. 8, eabp9435 (2022).
-
Majeau, N. et al. Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene. Mol. Ther. 30, 2429–2442 (2022).
-
Yao, X. et al. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing. J. Extracell. Vesicles 10, e12076 (2021).
-
Smyth, T. J., Redzic, J. S., Graner, M. W. & Anchordoquy, T. J. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim. Biophys. Acta 1838, 2954–2965 (2014).
-
Bonsergent, E. et al. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. Nat. Commun. 12, 1864 (2021).
-
Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653–658 (2013).
-
Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).
-
Chatterjee, S. et al. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).
-
Bernhard, N. et al. Nanoparticles as transfection agents: a comprehensive study with ten different cell lines. RSC Adv. 6, 18102–18112 (2016).
-
Reshke, R. et al. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat. Biomed. Eng. 4, 52–68 (2020).
-
Saber, N., Senti, M. E. & Schiffelers, R. M. Lipid nanoparticles for nucleic acid delivery beyond the liver. Hum. Gene Ther. 35, 617–627 (2024).
-
Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28–51 (2015).
-
Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8, 483–494 (2014).
-
Lee, C. S., Kulkarni, Y., Pierre, V., Maski, M. & Wanner, C. Adverse impacts of PEGylated protein therapeutics: a targeted literature review. BioDrugs 38, 795–819 (2024).
-
Simon, L. et al. Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation. Biomaterials 313, 122748 (2025).
-
Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).
-
Hosseini-Kharat, M., Bremmell, K. E. & Prestidge, C. A. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol. Ther. Methods Clin. Dev. 33, 101436 (2025).
-
Ochoa-Sánchez, C., Rodríguez-León, E., Iñiguez-Palomares, R. & Rodríguez-Beas, C. Brief comparison of the efficacy of cationic and anionic liposomes as nonviral delivery systems. ACS Omega 9, 46664–46678 (2024).
-
Cui, S. et al. Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol. Res. 7, 473–479 (2018).
-
Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100–109 (2006).
-
Lee, Y. et al. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).
-
Dong, X. et al. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: a double-blind, randomized, placebo-controlled study. Front. Immunol. 13, 1002938 (2022).
-
Driedonks, T. A. P., Jiang, L., Gololobova, O., Liao, Z. & Witwer, K. W. ELISA-based detection of immunoglobulins against extracellular vesicles in blood plasma. J. Extracell. Biol. 3, e129 (2024).
-
Cullis, P. R., Felgner, P. L., Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709–722 (2024).
-
Pattni, B. S., Chupin, V. V. & Torchilin, V. P. New developments in liposomal drug delivery. Chem. Rev. 115, 10938–10966 (2015).
-
Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095 (1993).
-
Gudbergsson, J. M. et al. Systematic review of factors influencing extracellular vesicle yield from cell cultures. Cytotechnology 68, 579–592 (2015).
-
Baker, M. & Baker, M. Reproducibility: respect your cells!. Nature 537, 7620 (2016).
-
Nguyen, V. V. T., Witwer, K. W., Verhaar, M. C., Strunk, D. & Balkom, B. W. M. V. Functional assays to assess the therapeutic potential of extracellular vesicles. J. Extracell. Vesicles 10, e12033 (2020).
-
Xu, S. et al. Comparison of nanoimaging and nanoflow based detection of extracellular vesicles at a single particle resolution. J. Extracell. Biol. 3, e70016 (2024).
-
Kobayashi, H. et al. Precise analysis of single small extracellular vesicles using flow cytometry. Sci. Rep. 14, 7465 (2024).
-
Woud, W. W. et al. An imaging flow cytometry-based methodology for the analysis of single extracellular vesicles in unprocessed human plasma. Commun. Biol. 5, 633 (2022).
-
Morales-Kastresana, A. et al. High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. J. Extracell. Vesicles 8, 1597603 (2019).
-
Welsh, J. A. et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J. Extracell. Vesicles 9, 1713526 (2020).
-
Zhang, J. et al. Immunomagnetic sequential ultrafiltration (iSUF) platform for enrichment and purification of extracellular vesicles from biofluids. Sci. Rep. 11, 8034 (2021).
-
Nizamudeen, Z. et al. Rapid and accurate analysis of stem cell-derived extracellular vesicles with super resolution microscopy and live imaging. Biochim. Biophys. Acta Mol. Cell Res. 1865, 1891–1900 (2018).
-
Jensen, E. & Crossman, D. J. Technical review: types of imaging — direct STORM. Anat. Rec. 297, 2227–2231 (2014).
-
McNamara, R. P. et al. Imaging of surface microdomains on individual extracellular vesicles in 3-D. J. Extracell. Vesicles 11, e12191 (2022).
-
Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).
